Phase II study of TAS-102 in patients with metastatic colorectal cancer
Phase 2
- Conditions
- Patients with non- resectable advanced metastatic colorectal cancer refractory or intolerable to fluoropyrimidine, irinotecan and oxaliplatin, who had a history of chemotherapy of 2 or more regimens.
- Registration Number
- JPRN-jRCT2080220849
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 162
Inclusion Criteria
1)Patients with colorecotal cancer, who had received prior therapy, at least two regimens, containing fluoropyrimidine, oxaliplatin, and irinotecan
2)Patients must be able to take orally
Exclusion Criteria
1)Patient who has serious concomitant disease
2)Patient who had received TAS-102
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method